市場調查報告書
商品編碼
1291591
非處方藥(OTC)市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測Over The Counter (OTC) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球非處方藥(OTC)市場規模達到1588億美元。展望未來,IMARC Group預計,到2028年,市場規模將達到2317億美元,在2023-2028年期間呈現6.24%的成長率(CAGR)。
非處方藥(OTC),也被稱為非處方藥,可以在沒有處方的情況下使用,也不需要尋求醫療專業人士的治療。它們安全有效,有助於治療疼痛、咳嗽和感冒、腹瀉、便秘、痤瘡和控制復發性偏頭痛和過敏。目前,它們在全球各地的藥店、便利店、超市和加油站都有銷售。
越來越多的人利用非處方藥來治療小病,這是促進市場成長的關鍵因素之一。除此之外,OTC藥物,如抗酸劑、組胺-2(H2)阻斷劑和質子泵抑製劑(PPI),被用來緩解和預防胃灼熱或消化不良。此外,由於冠狀病毒疾病(COVID-19)的爆發,個人對自我護理的重要性的認識也在提高。這反過來又增加了營養補充劑的銷售,加強了市場的成長。此外,主要參與者正在擴大他們的產品組合,以擴大他們的消費者基礎和增加他們的地理分佈。再加上監管機構擴大批准將處方藥轉換為非處方藥,這對市場產生了積極的影響。除此以外,由於醫療費用的增加,目前選擇非處方藥而不是諮詢醫生的人越來越多。此外,自我治療的做法可以幫助控制慢性疾病,減少缺勤,並節省稀缺的醫療資源,避免在小病中被耗盡。其他一些因素,如全球老年人口的增加,配銷通路的快速擴張,以及製藥業的大幅成長,都在推動整體銷售和盈利。
The global over the counter (OTC) drugs market size reached US$ 158.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 231.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.24% during 2023-2028.
Over the counter (OTC) drugs, also known as non-prescription drugs, can be used without a prescription or the need for seeking treatment by a healthcare professional. They are safe and effective and help cure pain, cough and cold, diarrhea, constipation, acne and manage recurring migraines and allergies. They are currently available in pharmacies, convenience stores, supermarkets and gas stations across the globe.
The increasing utilization of OTC drugs to treat minor ailments among individuals represents one of the key factors bolstering the market growth. Besides this, OTC medications, such as antacids, histamine-2 (H2) blockers, and proton pump inhibitors (PPIs), are used to relieve and prevent heartburn or acid indigestion. In addition, due to the coronavirus disease (COVID-19) outbreak, there is a rise in awareness among individuals about the importance of self-care. This, in turn, is increasing the sales of nutritional supplements and strengthening the market growth. Moreover, key players are expanding their product portfolio to widen their consumer base and increase their geographical presence. This, coupled with the increasing approvals from regulatory bodies for switching prescription drugs to OTC drugs, is positively influencing the market. Apart from this, there is currently an increase in the number of people opting for OTC drugs rather than consulting physicians on account of increasing healthcare costs. Furthermore, self-medication practices can assist in controlling chronic diseases, reducing absenteeism from work, and saving scarce medical resources from being exhausted during minor conditions. Some of the other factors, such as the rising geriatric population worldwide, rapid expansion of distribution channels, and significant growth in the pharmaceutical industry, are driving the overall sales and profitability.
IMARC Group provides an analysis of the key trends in each sub-segment of the global over the counter (OTC) drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, route of administration, dosage form and distribution channel.
Cough, Cold and Flu Products
Analgesics
Dermatology Products
Gastrointestinal Products
Vitamins, Minerals and Supplements (VMS)
Weight-loss/Dietary Products
Ophthalmic Products
Sleeping Aids
Others
Oral
Parenteral
Topical
Others
Tablets and Capsules
Liquids
Ointments
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alkem Laboratories Limited, Bayer AG, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Perrigo Company plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global over the counter (OTC) drugs market in 2022?
2. What is the expected growth rate of the global over the counter (OTC) drugs market during 2023-2028?
3. What are the key factors driving the global over the counter (OTC) drugs market?
4. What has been the impact of COVID-19 on the global over the counter (OTC) drugs market?
5. What is the breakup of the global over the counter (OTC) drugs market based on the product type?
6. What is the breakup of the global over the counter (OTC) drugs market based on the route of administration?
7. What is the breakup of the global over the counter (OTC) drugs market based on the dosage form?
8. What is the breakup of the global over the counter (OTC) drugs market based on the distribution channel?
9. What are the key regions in the global over the counter (OTC) drugs market?
10. Who are the key players/companies in the global over the counter (OTC) drugs market?